GL Pharm Tech Corp. Logo

GL Pharm Tech Corp.

Develops improved drugs and generics, and licenses proprietary drug formulation technologies.

204840 | KO

Overview

Corporate Details

ISIN(s):
KR7204840003
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 달래내로 46 성남글로벌융합센터 210호, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

GL Pharm Tech Corp. is a pharmaceutical company engaged in the research, development, manufacturing, and distribution of pharmaceutical products. The company specializes in creating Incrementally Modified Drugs (IMDs), which are improved versions of existing medications designed to offer benefits such as reduced side effects or modified-release formulations. It provides generic drugs and licenses its proprietary drug formulation and delivery platform technologies to other pharmaceutical firms. The company's core competency lies in developing innovative formulations to enhance the efficacy and patient profile of established therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-08 00:00
Regulatory News Service
불성실공시법인미지정 (지정유예)
Korean 5.6 KB
2025-08-25 00:00
Regulatory News Service
불성실공시법인지정예고 (공시번복)
Korean 4.9 KB
2025-08-14 00:00
M&A Activity
[기재정정]주요사항보고서(회사합병결정)
Korean 96.7 KB
2025-08-14 00:00
M&A Activity
기타주요경영사항 (회사 합병결정 철회)
Korean 7.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-07-03 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.7 KB
2025-07-03 00:00
M&A Activity
[첨부추가]주요사항보고서(회사합병결정)
Korean 94.9 KB
2025-05-12 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.3 MB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 24.6 KB
2025-03-26 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.9 KB
2025-03-26 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 14.3 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 25.9 KB
2025-03-18 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.7 MB
2025-03-11 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 14.3 KB
2025-03-11 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 159.7 KB

Automate Your Workflow. Get a real-time feed of all GL Pharm Tech Corp. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GL Pharm Tech Corp.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GL Pharm Tech Corp. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.